
Strategic Partnership Opportunity with Rockwell Automation/Plex
Prepared by Nagesh Nama
CEO, xLM Continuous Intelligence
February 2nd, 2026.
Rockwell's Plex platform is the industry's most advanced cloud-native ERP/MES—but pharmaceutical manufacturers won't adopt it because they can't validate it under 21 CFR Part 11 and ICH Q 7.
Traditional validation (CSV) requires full revalidation when software changes. Plex deploys updates weekly. The math doesn't work.
September 2025 CSA guidance explicitly permits risk-based, proportionate validation and endorses continuous deployment with automated testing—specifically to enable cloud SaaS adoption.
xLM becomes Plex's integrated validation engine.
Automated validation of Plex platform updates
Continuous Validation with 100% Regression
Provide Real-time Compliance for the Plex-Platform & Plex-Instances
The Result: Plex becomes the only continuously validated SaaS manufacturing platform for life sciences.
Creates regulatory permission for risk-based SaaS validation; However, xLM's technology can support continuous validation with 100% regression.
51% of manufacturers plan smart manufacturing adoption within 5 years, constrained by validation barriers
<10% of Plex's 700 customers are in life sciences (vs. 70% in discrete manufacturing)
Window of 12-24 months to establish market-leading "validated SaaS" position before competitors respond

Life sciences customers need proof that weekly Plex updates don't introduce compliance risks.
Automated regression testing of all GxP-critical functionality (audit trails, electronic signatures, data integrity, access controls).

Customers need ongoing assurance their Plex configuration remains in validated state.
Continuous monitoring agents tracking system configuration, data integrity, access controls, audit trail completeness.
Shifts support from "how do we validate?" to self-service compliance. Deepens customer relationships. Reduces support burden.
Configuration changes, customizations, and integrations trigger change control requirements. Manual assessment is slow and error-prone.
Automated change impact assessment, risk proportionalization, documentation generation, and post-change verification.
Enables rapid Plex customization with compliance confidence. Reduces change cycle time from 8-12 weeks to hours.
Plex competes against Körber PAS-X, L 7 Informatics, Siemens, and Dassault. Plex's advantage: cloud-native, single-instance SaaS, global scale. But without solved validation story, these advantages are abstract.
The company that solves validated SaaS for life sciences will capture 40-50% of the market.
FDA CSA guidance creates 12-24 month first-mover advantage. If Rockwell moves decisively, it can establish market-leading position in "validated, continuously deployed manufacturing software" before competitors develop similar solutions.
Initial partnership framework meeting (Alex, Anthony, Devin + xLM team)
Technical architecture deep-dive (engineering + product teams)
Commercial terms negotiation
Phase 1 kickoff (CIV-Platform for Plex 2026.03 release)
White paper publication + pilot customer recruitment
Phase 1 completion, market launch readiness
Problem: Rockwell releases updates to the Plex platform every 1-2 weeks. Life sciences customers need proof that those updates don't introduce risks to validated processes, data integrity, or regulatory compliance.
xLM Solution: Automated, continuous validation of Plex platform updates in near-real-time.
How It Works:
Business Impact for Rockwell:
Life sciences customers need ongoing proof that their specific Plex configuration—with custom workflows, integrations, and data—remains in validated state as they operate and as Plex platform updates deploy.
Continuous monitoring and validation of customer Plex instances.
Problem: Configuring Plex, customizing workflows, or integrating with other systems triggers essential change control and impact assessment. Manually evaluating each change is resource-intensive and prone to errors.
xLM Solution: Automated change impact assessment and CSPA (Change Sustainability and Performance Assessment) for all Plex-based modifications.
This proposal is confidential and intended solely for Rockwell Automation's leadership team. Unauthorized distribution is prohibited.
All financial projections and ROI estimates are based on typical xLM client results and industry benchmarks. Actual results may vary based on Rockwell Automation's specific operational context.
xLM Continuous Intelligence reserves the right to update this proposal based on additional discovery and alignment discussions with Rockwell Automation.
Executive Summary: xLM Continuous Intelligent Validation